Loading
225Ac/64Cu-PD-29875 (Claudin 18.2) is an experimental radioligand peptide-drug conjugate from PeptiDream, in preclinical development for gastric cancer.
225Ac/64Cu-PD-29875 (Claudin 18.2) (PD-29875) is a radioligand peptide-drug conjugate (RI-PDC) from PeptiDream. A peptide-radioisotope conjugate against Claudin 18.2, for diagnosis and treatment of gastric cancer. Its furthest stage is preclinical development, for gastric cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline lists IND-enabling for both therapeutic and diagnostic. It has not been shown to work in people.
A peptide-radioisotope conjugate against Claudin 18.2, for diagnosis and treatment of gastric cancer. Connects to Claudin 18.2.
1.225Ac/64Cu-PD-29875 (Claudin 18.2)'s antibody arm binds Claudin 18.2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"225Ac/64Cu-PD-29875" OR ABSTRACT:"225Ac/64Cu-PD-29875" OR TITLE:"Claudin 18.2" OR ABSTRACT:"Claudin 18.2" OR TITLE:"PD-29875" OR ABSTRACT:"PD-29875") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 225Ac/64Cu-PD-29875 (Claudin 18.2), not a curated reading list.
Shares PeptiDream and the tag pipeline.
Shares PeptiDream and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/